Senolytic Effect Biomarkers: p16, SA-β-Gal, and Circulating SASP Factors

Expert Summary

Clinical senolytic trials use a combination of tissue biomarkers (p16, p21, SA-β-Gal from biopsies) and circulating biomarkers (IL-6, MMP-3, MMP-9, GDF15 from blood) to assess treatment efficacy. For self-directed monitoring without biopsy access, circulating inflammatory markers (IL-6, hsCRP) and functional assessments (gait speed, grip strength) provide the most practical evidence of senolytic activity.

Key Facts

Frequently Asked Questions

What's the most practical biomarker panel for monitoring my own senolytic protocol?

Start with: hsCRP, IL-6, and GDF15 from a commercial lab. These three capture different aspects of senescent cell burden at low cost. Measure before starting, after 3 months, and every 6 months ongoing.

Where can I get p16 mRNA testing?

Specialized companies including Life Length (telomere + senescence), TruDiagnostic (epigenetic age + inflammation), and some academic labs offer p16 blood testing. Standard commercial labs do not currently provide this.

Scientific References

Practical interpretation

Markers such as p16, beta-galactosidase, or SASP-related factors are not interchangeable and may reflect several biological processes. No single blood test confirms senescent-cell burden in an individual or proves that a therapy removed those cells. Ask how a result is validated before paying for serial testing or changing treatment.

Senescence research distinguishes cell and animal mechanisms from demonstrated human health outcomes. A change in a marker does not prove that senescent cells were cleared or that symptoms, disease risk, or lifespan changed. No self-directed preventive dose or schedule is established. Do not use prescription drugs or high-dose supplements as an online protocol; discuss relevant symptoms and treatments with a clinician.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.